Oestrogen-free oral contraception with a 4 mg drospirenone-only pill: new data and a review of the literature

References

• World Health Organization. Medical eligibility criteria for contraceptive use. 5th ed. Geneva: WHO; 2015.
   Google Scholar
• European Medicines Agency. Combined hormonal contraceptives. Available from: www.ema.europa.eu/en/medicines/human/referrals/combined-hormonal-contraceptives.
   Google Scholar
• Schindler AE. Non-contraceptive benefits of oral hormonal contraceptives. Int J Endocrinol Metab. 2013;11:41–47.
   PubMedGoogle Scholar
• Schindler AE, Campagnoli C, Druckmann R, et al. Classification and pharmacology of progestins. Maturitas. 2008;61:171–180.
   PubMed Web of Science ®Google Scholar
• Regidor PA, Schindler AE. Antiandrogenic and antimineralocorticoid health benefits of COC containing newer progestins: dienogest and drospirenone. Oncotarget. 2017;8:83334–83342.
   PubMedGoogle Scholar
• Rice CF, Killick SR, Dieben T, Bennink HC. A comparison of the inhibition of ovulation achieved by desogestrel 75 mg and levonorgestrel 30 mg daily. Hum Reprod 1999;14:982–985.
   PubMed Web of Science ®Google Scholar
• Sarfati J, de Vernejoul MC. Impact of combined and progestin-only contraceptives on bone mineral density. Joint Bone Spine. 2009;76;134–138.
   PubMed Web of Science ®Google Scholar
• Rice C, Killick S, Hickling D, Bennink HC. Ovarian activity and vaginal bleeding patterns with a desogestrel-only preparation at three different doses. Hum Reprod. 1996;11:737–740.
   PubMed Web of Science ®Google Scholar
• de Melo NR. Estrogen-free oral hormonal contraception: benefits of the progestin-only pill. Women’s Health (Lond). 2010;6:721–735.
   PubMedGoogle Scholar
• Bayer HealthCare Pharmaceuticals. (2015). Yaz. Summary of product characteristics. Available from: https://db.cbg-meb.nl/mri/spc/nlh-1269-001.pdf.
   Google Scholar
• MSD. (2011). Zoely. Summary of product characteristics. Available from: www.medicines.org.uk/emc/product/3038/smpc.
   Google Scholar
• Regidor PA. The clinical relevance of progestins in hormonal contraception: present status and future developments. Oncotarget. 2018;9:34628–34638.
   PubMedGoogle Scholar
• Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestin. Contraception. 2000;62:29–38.
   PubMed Web of Science ®Google Scholar
• Richter WH, Koytchev R, Kirkov V, et al. Comparative pharmacokinetic estimates of drospirenone alone and in combination with ethinyl estradiol after single and repeated oral administration in healthy females. Contraception. 2020;101:137–143.
   PubMed Web of Science ®Google Scholar
• Rohn KJ, Cook IT, Leyh TS, et al. Potent inhibition of human sulfotransferase 1A1 by 17α-ethinylestradiol: role of 3′-phosphoadenosine 5′-phosphosulfate binding and structural rearrangements in regulating inhibition and activity. Drug Metab Dispos. 2012;40:1588–1595.
   PubMed Web of Science ®Google Scholar
• Duijkers IJ, Heger-Mahn D, Drouin D, Skouby S. A randomised study comparing the effect on ovarian activity of a progestogen-only pill (POP) containing desogestrel and a new POP containing drospirenone in a 24/4 regimen. Eur J Contracept Reprod Health Care. 2015;20:419–427.
   PubMed Web of Science ®Google Scholar
• Duijkers IJM, Heger-Mahn D, Drouin D, et al. Maintenance of ovulation inhibition with a new progestogen-only pill containing drospirenone after scheduled 24-h delays in pill intake. Contraception. 2016;93:303–309.
   PubMed Web of Science ®Google Scholar
• Archer DF, Ahrendt HJ, Drouin D. Drospirenone-only oral contraceptive: results from a multicenter noncomparative trial of efficacy, safety and tolerability. Contraception. 2015;92:439–444.
   PubMed Web of Science ®Google Scholar
• Palacios S, Colli E, Regidor PA. Multicenter, phase III trials on the contraceptive efficacy, tolerability and safety of a new drospirenone-only pill. Acta Obstet Gynecol Scand. 2019;98:1549–1557.
   PubMed Web of Science ®Google Scholar
• Kimble T, Burke AE, Barnhart KT, et al. A 1-year prospective, open-label, single-arm, multicenter, phase 3 trial of the contraceptive efficacy and safety of the oral progestin-only pill drospirenone 4 mg, using a 24/4-day regimen. Contraception. 2:100020.
   Google Scholar
• Regidor PA, Colli E, Schindler AE. Drospirenone as estrogen-free pill and hemostasis: coagulatory study results comparing a novel 4 mg formulation in a 24 + 4 cycle with desogestrel 75 μg per day. Gynecol Endocrinol. 2016;32:749–751.
   PubMed Web of Science ®Google Scholar
• Oelkers W, Foidart JM, Dombrovicz N, et al. Effects of a new oral contraceptive containing an antimineralocorticoid progestin, drospirenone, on the renin–aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab. 1995;80:1816–1821.
   PubMed Web of Science ®Google Scholar
• Gaspard U, Scheen A, Endrikat J, et al. A randomized study over 13 cycles to assess the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on carbohydrate metabolism. Contraception. 2003;67:423–429.
   PubMed Web of Science ®Google Scholar
• Hadji P, Colli E, Regidor PA. Bone health in estrogen-free contraception. Osteoporos Int. 2019;30:2391–2400.
   PubMed Web of Science ®Google Scholar
• Doran PM, Riggs BL, Atkinson EJ, Khosla S. Effects of raloxifene, a selective estrogen receptor modulator, on bone turnover markers and serum sex steroid and lipid levels in elderly men. J Bone Miner Res. 2001;16:2118–21125.
   PubMed Web of Science ®Google Scholar
• Foidart JM, Faustmann T. Advances in hormone replacement therapy: weight benefits of drospirenone, a 17α-spirolactone-derived progestogen. Gynecol Endocrinol. 2007;23:692–699.
   PubMed Web of Science ®Google Scholar
• Palacios S, Colli E, Regidor PA. A multicenter, double-blind, randomized trial on the bleeding profile of a drospirenone-only pill 4 mg over nine cycles in comparison with desogestrel 0.075 mg. Arch Gynecol Obstet. 2019;300:1805–1812.
   PubMed Web of Science ®Google Scholar
• Regidor PA, Colli E, Georgiev D, et al. Safety, influence on the endometrium, sonographic changes and bleeding profile after 13 cycles with the new drospirenone only pill (DOP) for contraception. Horm Mol Biol Clin Investig. 2020. doi: 10.1515/hmbci-2019-0061
   PubMedGoogle Scholar
• Apter D, Enrico E, Gemzell Danielsson K, Klaus Peters K. Multicenter, open-label trial to assess the safety and tolerability of drospirenone 4.0 mg over 6 cycles in female adolescents, with a 7-cycle extension phase. Presented at 19th FIGIJ World Congress of Paediatric and Adolescent Gynecology, Melbourne, VIC, 2019; 176.
   Google Scholar
• Ng M, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013.Lancet. 2014;384:766–781.
   PubMed Web of Science ®Google Scholar
• Exeltis. (2019). Slynd. Available from: www.drugs.com/pro/slynd.html.
   Google Scholar